← Back to headlines
Replimune Stock Plummets After FDA Rejection
Replimune Group Inc. saw its stock price fall by 64% after the U.S. Food and Drug Administration rejected its application for a new drug.
14 Apr, 18:03 — 14 Apr, 18:03
Sources
Showing 1 of 1 sources
